- Home
- Clinical Fields
- Theranostics
Theranostics for personalized
cancer careEmpowering precision oncology
Theranostics at a glance
Cancer incidence rates are rising
Cancer incidence rates continue to rise worldwide with an expectation of 28 million new cases by 2040.1 Taking this outlook into consideration, we are reminded of the need to prioritize precision oncology.
Theranostics enables precision oncology
Theranostics (ie, "therapy" + "diagnostics") is an innovative approach to personalized cancer care that involves the use of molecular imaging (eg, PET/CT and SPECT/CT) and radiopharmaceuticals to tailor treatments to an individual patient. It involves the combination of one diagnostic radioactive drug to "see" the disease and a second therapeutic radioactive drug to deliver therapy to "treat" the disease.
The future of theranostics
From new radiopharmaceutical therapy development to expanding clinical indications, the adoption of theranostics into clinical practice continues to grow. This growth is triggering the up-scaling of existing and new theranostics centers to meet the demand for this type of personalized, predictive, and precise cancer treatment.
Types of cancer treated with theranostics
The current impact of theranostics is greatest in oncology, where it already plays a key role in the management of prostate cancer, neuroendocrine tumors, thyroid cancer, and liver cancer.
Thyroid cancer
Neuroendocrine tumors
Liver cancer
Prostate cancer
Theranostics care pathway
Understanding the patient pathway
Diagnosis and patient selection
A radioactive drug and imaging exams help physicians identify cancer cells
Personalized treatment
After cancer cells are identified, the right treatment can be selected and delivered
Therapy response monitoring
Molecular imaging tools help monitor the patient's therapy response
Follow-up and survivorship monitoring
Additional imaging exams and patient engagement tools can help monitor survivorship
Patient journeys
Every patient's theranostics journey is different. Explore these patient stories to learn more.
Theranostics for neuroendocrine tumors: Glenda's journey
Meet the care team
Scott Degenhardt, director of radiology and theranostics, and Marlene Bridwell, theranostics nurse case manager at NCS, highlight the importance of having the right technology and staffing infrastructure in place to help care for patients throughout their theranostics journey.
Meet Glenda
After receiving the diagnosis of neuroendocrine tumors, Glenda's oncologist was unable to provide effective treatment options. Considering her disease burden and noting the progression of the tumors that were difficult to surgically remove, Glenda was referred to Nebraska Cancer Specialists (NCS) for theranostics treatment.
Meet the physicians
Samuel Mehr, MD, director of nuclear oncology and Joel Michalski, MD, PhD, medical oncologist at NCS describe the benefits of offering theranostics within a medical oncology practice and how this creates a patient-centered approach to personalized cancer care for patients like Glenda.
Meet the care team
Scott Degenhardt, director of radiology and theranostics, and Marlene Bridwell, theranostics nurse case manager at NCS, highlight the importance of having the right technology and staffing infrastructure in place to help care for patients throughout their theranostics journey.
Meet Glenda
After receiving the diagnosis of neuroendocrine tumors, Glenda's oncologist was unable to provide effective treatment options. Considering her disease burden and noting the progression of the tumors that were difficult to surgically remove, Glenda was referred to Nebraska Cancer Specialists (NCS) for theranostics treatment.
Meet the physicians
Samuel Mehr, MD, director of nuclear oncology and Joel Michalski, MD, PhD, medical oncologist at NCS describe the benefits of offering theranostics within a medical oncology practice and how this creates a patient-centered approach to personalized cancer care for patients like Glenda.
Meet the care team
Scott Degenhardt, director of radiology and theranostics, and Marlene Bridwell, theranostics nurse case manager at NCS, highlight the importance of having the right technology and staffing infrastructure in place to help care for patients throughout their theranostics journey.
Theranostics for prostate cancer: John's journey
Meet John
Enabled by molecular imaging technology, theranostics using a PSMA-targeted radioligand therapeutic agent has the potential to enhance and prolong life for prostate cancer patients such as John. "I was able to feel more of myself. It was remarkable," he says.
Establishing a theranostics program
Getting started
Implementing a theranostics program into an existing practice requires a comprehensive set of considerations including technology investments, staff training, regulatory compliance, strategic partnerships, and financial planning.
Explore our practical guide to learn how to build a successful theranostics program.
Theranostics program implementation checklist
Refer to this implementation checklist of considerations as you start designing your theranostics program.
Trusted expertise to help with implementation
Explore these virtual tours to see how we're collaborating with healthcare institutions to help them integrate theranostics into practice.
Department for theranostics
Creating your unique radiopharmaceutical therapy center of excellence
Theranostics in clinical practice
Discover how our customers are integrating theranostics into everyday clinical practice.
Theranostics center of excellence: transforming oncology care
Nebraska Cancer Specialists in the midwestern region of the United States serves as a model of excellence in theranostics. While caring for the local community and attracting patients from across the country, the center also operates an extensive clinical trials program.
Growing theranostics program is now everyday clinical practice in Finland
As a true pioneer in the frontier in cancer treatment, The Comprehensive Cancer Center in Helsinki offers precision therapy personalized to the needs of each individual patient.
Theranostics offers personalized care for prostate cancer
Professor Joseph R. Osborne, MD, PhD, chief of Molecular Imaging and Therapeutics, and professor of radiology at a leading academic institution’s hospital in New York City, New York, USA, discusses theranostics and its rapidly expanding role in prostate cancer care.
Your trusted partner in theranostics
Precision oncology tools at every step of the theranostics care pathway
There is no one-size-fits-all approach to theranostics, so no matter where your institution is on its theranostics journey, we want to empower you with the tools you need to plan, implement, and expand your program to meet the demands of tomorrow.
Establish an innovative theranostics program for tomorrow with confidence in our comprehensive value chain and trusted expertise. We are committed to personalizing theranostics solutions for you, so you can focus on personalizing care for patients.
Molecular imaging
Therapy solutions
Software solutions
Laboratory diagnostics
Targeted development
Ready to establish your theranostics program?
Let's help patients get the right treatment at the right time.